Sugi Predict

Sugi Predict / Compounds / SCHEMBL2121003

SCHEMBL2121003

SCHEMBL2121003

COCCN(Cc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1)C(=O)O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 19/20 0.78
▸ KDR P35968 19/20 0.78
▸ MST1R Q04912 2/20 0.78
▸ AXL P30530 2/20 0.78
▸ FLT3 P36888 2/20 0.78
▸ PLK4 O00444 1/20 0.78
▸ MAP4K4 O95819 1/20 0.78
▸ ABL1 P00519 1/20 0.78
▸ LCK P06239 1/20 0.78
▸ FYN P06241 1/20 0.78
▸ LYN P07948 1/20 0.78
▸ HCK P08631 1/20 0.78
▸ PDGFRB P09619 1/20 0.78
▸ BCR P11274 1/20 0.78
▸ SRC P12931 1/20 0.78
▸ ABL2 P42684 1/20 0.78
▸ FRK P42685 1/20 0.78
▸ SYK P43405 1/20 0.78
▸ DDR1 Q08345 1/20 0.78
▸ MERTK Q12866 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL106729 0.92 MET (0.73) METKDRMST1RAXLFLT3
SCHEMBL103919 0.88 MET (0.61) METKDRMST1RAXLFLT3
SCHEMBL2533066 0.88 MET (0.73) METKDRMST1RAXLFLT3
SCHEMBL104141 0.88 MET (0.82) METKDRMST1RAXLFLT3
SCHEMBL16177258 0.88 MET (0.59) METKDRMST1RAXLFLT3
SCHEMBL3652049 0.87 MET (0.73) METKDRMST1RAXLFLT3
Glesatinib SCHEMBL106319 0.87 MET (1.00) METKDRMST1RAXLFLT3
Glesatinib SCHEMBL29351360 0.87 MET (1.00) METKDRMST1RAXLFLT3
SCHEMBL2670807 0.87 MST1R (0.60) METKDRMST1RAXLFLT3
SCHEMBL2536266 0.87 MET (0.89) METKDRMST1RAXLFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2426108-B1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC (CA) 2016-08-10 — — EP disclosed
US-8907091-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2014-12-09 — — US disclosed
US-20130310564-A1 Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors METHYLGENE INC. (CA) 2013-11-21 — — US disclosed
US-8569503-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2013-10-29 — — US disclosed
US-20120095234-A1 PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS Mirati Therapeutics, Inc. 2012-04-19 — — US disclosed
US-20090286984-A1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors Mirati Therapeutics, Inc. 2009-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095234-A1 PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS MAP3K19, MAP3K9, MAP4K2 MET 1062/4885KDR 526/4885MST1R 759/4885
US-20130310564-A1 Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors MAP3K19, MAP3K15, MAP3K9 MET 916/4885KDR 535/4885MST1R 673/4885
US-20090286984-A1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors MAP3K19, MAP3K9, MAP4K2 MET 1062/4885KDR 526/4885MST1R 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.